Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CYBN
Upturn stock ratingUpturn stock rating

Cybin Inc (CYBN)

Upturn stock ratingUpturn stock rating
$7.94
Last Close (24-hour delay)
Profit since last BUY-4.8%
upturn advisory
WEAK BUY
BUY since 27 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: CYBN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $86.51

1 Year Target Price $86.51

Analysts Price Target For last 52 week
$86.51 Target price
52w Low $4.81
Current$7.94
52w High $13.88

Analysis of Past Performance

Type Stock
Historic Profit -57.32%
Avg. Invested days 19
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 183.05M USD
Price to earnings Ratio -
1Y Target Price 86.51
Price to earnings Ratio -
1Y Target Price 86.51
Volume (30-day avg) 5
Beta 1.13
52 Weeks Range 4.81 - 13.88
Updated Date 07/5/2025
52 Weeks Range 4.81 - 13.88
Updated Date 07/5/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.1

Earnings Date

Report Date 2025-07-01
When -
Estimate -0.0248
Actual -1.46

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -44.06%
Return on Equity (TTM) -57.49%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 69593248
Price to Sales(TTM) 278.25
Enterprise Value 69593248
Price to Sales(TTM) 278.25
Enterprise Value to Revenue 313.59
Enterprise Value to EBITDA -3.79
Shares Outstanding 23023600
Shares Floating 17009015
Shares Outstanding 23023600
Shares Floating 17009015
Percent Insiders -
Percent Institutions 48.73

ai summary icon Upturn AI SWOT

Cybin Inc

stock logo

Company Overview

overview logo History and Background

Cybin Inc. is a biopharmaceutical company focused on developing psychedelic-based therapeutics. Founded in 2019, Cybin has rapidly advanced clinical trials and research into novel psychedelic molecules to address unmet mental health needs. It has grown through acquisitions and partnerships.

business area logo Core Business Areas

  • Drug Discovery and Development: Focuses on discovering and developing novel psychedelic compounds and delivery systems for mental health disorders.
  • Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its psychedelic-based therapeutics.

leadership logo Leadership and Structure

Doug Drysdale serves as the Chief Executive Officer. The company has a board of directors and various departments responsible for research, development, clinical operations, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • CYB003: A proprietary psilocybin analog being developed for the treatment of Major Depressive Disorder (MDD). Market share is currently not applicable as it is still under development. Competitors include companies working on psilocybin therapies such as COMPASS Pathways (CMPS) and Atai Life Sciences (ATAI).
  • CYB004: A deuterated DMT molecule being developed for anxiety disorders. Market share is currently not applicable as it is still under development. Competitors include small companies working with DMT.

Market Dynamics

industry overview logo Industry Overview

The psychedelic therapeutics industry is emerging and rapidly growing, driven by increasing awareness of mental health challenges and the potential of psychedelic compounds to address these issues. Regulatory environments are evolving to accommodate research and potential approval of psychedelic therapies.

Positioning

Cybin is positioned as a leader in the development of novel psychedelic molecules and delivery systems. Its competitive advantage lies in its proprietary drug candidates and clinical trial programs.

Total Addressable Market (TAM)

The TAM for mental health treatments is substantial, estimated in the tens of billions of dollars annually. Cybin is positioned to capture a portion of this market with its innovative therapies. The TAM for depression alone is estimated at $15 billion by 2030.

Upturn SWOT Analysis

Strengths

  • Proprietary drug candidates
  • Strong intellectual property portfolio
  • Experienced leadership team
  • Focus on novel psychedelic molecules
  • Advanced clinical trials

Weaknesses

  • High cash burn rate
  • Dependence on capital markets for funding
  • Regulatory uncertainties
  • Early-stage development risk
  • Limited revenue generation

Opportunities

  • Potential FDA approval of psychedelic therapies
  • Partnerships with pharmaceutical companies
  • Expansion into new indications
  • Increasing acceptance of psychedelic treatments
  • Growing market demand for mental health solutions

Threats

  • Regulatory hurdles
  • Competition from other psychedelic companies
  • Clinical trial failures
  • Negative public perception
  • Intellectual property challenges

Competitors and Market Share

competitor logo Key Competitors

  • CMPS
  • ATAI
  • GHRS

Competitive Landscape

Cybin differentiates itself through its focus on deuterated molecules and novel delivery systems. Competitors like COMPASS Pathways are further along in clinical development with psilocybin therapies.

Growth Trajectory and Initiatives

Historical Growth: Growth is characterized by the expansion of its drug development pipeline and advancement of clinical trials.

Future Projections: Future growth depends on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates suggest significant revenue potential if CYB003 or CYB004 are approved.

Recent Initiatives: Recent initiatives include the advancement of CYB003 into Phase 2 clinical trials and the initiation of preclinical studies for new psychedelic molecules.

Summary

Cybin is a speculative investment in the rapidly evolving psychedelic therapeutics industry. While the company possesses promising drug candidates and a strong intellectual property portfolio, it faces significant regulatory and financial hurdles. Successful clinical trial outcomes and potential FDA approval are crucial for future success, but its lack of revenue generation and dependence on capital markets poses risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Investor presentations
  • Press releases
  • Analyst reports
  • Industry news sources

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. The psychedelic therapeutics industry is highly speculative, and investors should conduct their own due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cybin Inc

Exchange NYSE MKT
Headquaters Toronto, ON, Canada
IPO Launch date 2019-09-13
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 50
Full time employees 50

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.